Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea J. Pereira de Santana Gomes, Karina Vianna, Hong Luo, Geoffrey T. Gotto, Heather H. Cheng, Won Kim, Carly R. Varela, Daneen Schaeffer, Kassie Kramer, Susan Li, Benoit Baron, Fei Shen, Suneel D. Mundle, Sharon A. McCarthy, David Olmos, Kim N. Chi, Dana E. Rathkopf

Open source

DOI: 10.1038/s41591-025-03961-8
Published: 2025-10-07
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-025-03961-8,
  title = {Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial},
  author = {Gerhardt Attard and Neeraj Agarwal and Julie N. Graff and Shahneen Sandhu and Eleni Efstathiou and Mustafa Özgüroğlu and Andrea J. Pereira de Santana Gomes and Karina Vianna and Hong Luo and Geoffrey T. Gotto and Heather H. Cheng and Won Kim and Carly R. Varela and Daneen Schaeffer and Kassie Kramer and Susan Li and Benoit Baron and Fei Shen and Suneel D. Mundle and Sharon A. McCarthy and David Olmos and Kim N. Chi and Dana E. Rathkopf},
  year = {2025},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-025-03961-8},
  url = {https://doi.org/10.1038/s41591-025-03961-8}
}

RIS

TY  - JOUR
TI  - Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
AU  - Gerhardt Attard
AU  - Neeraj Agarwal
AU  - Julie N. Graff
AU  - Shahneen Sandhu
AU  - Eleni Efstathiou
AU  - Mustafa Özgüroğlu
AU  - Andrea J. Pereira de Santana Gomes
AU  - Karina Vianna
AU  - Hong Luo
AU  - Geoffrey T. Gotto
AU  - Heather H. Cheng
AU  - Won Kim
AU  - Carly R. Varela
AU  - Daneen Schaeffer
AU  - Kassie Kramer
AU  - Susan Li
AU  - Benoit Baron
AU  - Fei Shen
AU  - Suneel D. Mundle
AU  - Sharon A. McCarthy
AU  - David Olmos
AU  - Kim N. Chi
AU  - Dana E. Rathkopf
PY  - 2025
JO  - Nature Medicine
DO  - 10.1038/s41591-025-03961-8
UR  - https://doi.org/10.1038/s41591-025-03961-8
ER  -

APA

Attard, G., Agarwal, N., Graff, J. N., Sandhu, S., Efstathiou, E., Özgüroğlu, M., Gomes, A. J. P. D. S., Vianna, K., Luo, H., Gotto, G. T., Cheng, H. H., Kim, W., Varela, C. R., Schaeffer, D., Kramer, K., Li, S., Baron, B., Shen, F., Mundle, S. D., McCarthy, S. A., Olmos, D., Chi, K. N., & Rathkopf, D. E. (2025). Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03961-8

Source records

crossref · retrieved 2026-09-26T05:27:23.246Z